Compare ARK Space & Defense Innovation ETF (ARKX) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ARK Space & Defense Innovation ETF vs Merck & Co., Inc. — how do they compare? ARK Space & Defense Innovation ETF trades at $31.8, while Merck & Co., Inc. trades at $123.84 (market cap $305.12B). The key difference: Merck & Co., Inc. pays a 2.75% dividend while ARK Space & Defense Innovation ETF pays none, and Merck & Co., Inc. is trading nearer its 52-week high, ARK Space & Defense Innovation ETF nearer its low. Which is the better fit depends on your goals.
| ARKX | MRK | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $37.74 | $129.52 |
52-Week Low | $24.97 | $77.60 |
Market Cap | — | $305.12B |
Enterprise Value | — | $348.54B |
Dividend Yield | — | 2.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARK Space Exploration & Innovation ETF (ARKX) trades at $32.05, down 0.82% today amid bearish technical signals. The ETF shows neutral oscillator readings but bearish moving averages, with key support at $32 and resistance at $33. Recent news highlights ARKX as a popular alternative to direct SpaceX investment, with the space economy reaching $500 billion in backlog according to 24/7 Wall Street (2026-07-06).
ARKX offers diversified exposure to the growing space sector without single-stock IPO risk. The ETF's higher volatility and expense ratio compared to traditional aerospace ETFs present both growth potential and increased risk. SpaceX's 8.31% weighting provides significant upside exposure but also concentration risk in a high-valuation name.
Merck (MRK) trades at $123.54, down 1.22% today, with a bullish technical signal from moving averages and a consensus analyst price target of $135.14. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of -$1.28 beating expectations. Revenue grew to $65.01B in 2025, and net income reached $18.25B, reflecting a robust 28.07% profit margin. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, signaling strategic growth initiatives.
The outlook for MRK remains positive driven by earnings momentum and strategic acquisitions, though risks include rising debt levels and competitive pressures. Wall Street sentiment is bullish with 68% buy ratings, but investors should monitor execution of the Terns integration and patent expirations. The stock offers potential upside to the price target with solid fundamentals supporting long-term value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ARK Space & Defense Innovation ETF
ARKX is an actively managed ETF that invests in companies leading space exploration and defense innovation. It focuses on orbital and sub-orbital aerospace, reusable rockets, and enabling technologies like AI, robotics, and satellite systems.
Read more on ARKX →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
